Drug · CHEMBL325041

BORTEZOMIB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. BORTEZOMIB. Drugs and targets, record CHEMBL325041. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL325041

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: BORTEZOMIB; ChEMBL
ChEMBL ID: CHEMBL325041; ChEMBL
Type: Small molecule; ChEMBL
Other names: Bortezomib hydrate, LDP-341, NSC-681239, PS-341; ChEMBL
Other form: BORTEZOMIB D-MANNITOL, CHEMBL5315122; Drugs and targets
DrugBank: DB00188; DrugBank
InChIKey: GXJABQQUPOEUTA-RDJZCZTQSA-N; ChEMBL
Open Targets' highest stage: Approval, for 3 of its 156 diseases, from ATC, EMA Human Drugs, PMDA and TTD; Open Targets

Targets38

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
ADRM1	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/11047
PSMA1	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/5682
PSMA2	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/5683
PSMA3	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/5684
PSMA4	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/5685
PSMA5	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/5686
PSMA6	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/5687
PSMA7	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/5688
PSMA8	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/143471
PSMB1	26S proteasome	26S proteasome inhibitor	INHIBITOR	https://conductscience.org/library/genes/5689

1 to 10 of 38Source ChEMBL

See all 38 targets

Diseases156

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
plasma cell myeloma	Approval	EMA Human Drugs, PMDA and TTD	465	458	https://conductscience.org/library/drugs?q=MONDO_0009693
mantle cell lymphoma	Approval	TTD	49	48	https://conductscience.org/library/drugs?q=MONDO_0018876
non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov and TTD	31	30	https://conductscience.org/library/drugs?q=MONDO_0018908
acute lymphoblastic leukemia	Phase 3	ClinicalTrials.gov	25	25	https://conductscience.org/library/drugs?q=MONDO_0004967
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	25	25	https://conductscience.org/library/drugs?q=MONDO_0018874
follicular lymphoma	Phase 3	ClinicalTrials.gov	24	24	https://conductscience.org/library/drugs?q=MONDO_0018906
non-small cell lung carcinoma	Phase 2	ClinicalTrials.gov	24	24	https://conductscience.org/library/drugs?q=MONDO_0005233
Waldenstrom macroglobulinemia	Phase 3	ClinicalTrials.gov	23	23	https://conductscience.org/library/drugs?q=MONDO_0100280
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	20	20	https://conductscience.org/library/drugs?q=MONDO_0018905
lymphoma	Phase 3	ClinicalTrials.gov	17	17	https://conductscience.org/library/drugs?q=MONDO_0005062

1 to 10 of 156Source Open Targets

See all 156 diseases

Trials950

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 3	1,645	2020-07-07	bortezomib	Its name	ClinicalTrials.gov
NCT02541383	A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma	Phase 3	1,085	2025-04-13	bortezomib	Its name	ClinicalTrials.gov
NCT02112916	Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma	Phase 3	847	2022-02-23	bortezomib	Its name	ClinicalTrials.gov
NCT01023308	Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma	Phase 3	767	2015-10-23	bortezomib	Its name	ClinicalTrials.gov
NCT01109004	Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)	Phase 3	758	2018-06-11	bortezomib	Its name	ClinicalTrials.gov
NCT01208662	Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65	Phase 3	729	2023-12-18	bortezomib	Its name	ClinicalTrials.gov
NCT03710603	Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma	Phase 3	709	2024-12-24	bortezomib	Its name	ClinicalTrials.gov
NCT02195479	A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma	Phase 3	706	2018-12-17	bortezomib	Its name	ClinicalTrials.gov
NCT00312845	Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	Phase 3	676	2011-07-26	bortezomib	Its name	ClinicalTrials.gov
NCT00103506	Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma	Phase 3	646	2015-05-25	bortezomib	Its name	ClinicalTrials.gov

1 to 10 of 950

See all 950 trials

Comparisons in its trials181

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm A Part 1 vs Arm B Part 1: Post-Consolidation Stringent Complete Response (sCR) Rate	110 of 542	157 of 543	1,085	NCT02541383	Trial comparisons
PAN+BTZ vs PBO+BTZ: serious adverse events	228 of 381	157 of 377	758	NCT01023308	Trial comparisons
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Progression Free Survival (PFS)	103 of 354	50 of 355	709	NCT03710603	Trial comparisons
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): deaths from any cause	44 of 354	34 of 355	709	NCT03710603	Trial comparisons
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Overall MRD Negativity Rate	168 of 354	267 of 355	709	NCT03710603	Trial comparisons
Velcade, Melphalan and Prednisone (VMP) vs Daratumumab, Velcade, Melphalan and Prednisone (D-VMP): deaths from any cause	217 of 356	172 of 350	706	NCT02195479	Trial comparisons
Velcade, Melphalan and Prednisone (VMP) vs Daratumumab, Velcade, Melphalan and Prednisone (D-VMP): serious adverse events	117 of 354	186 of 346	700	NCT02195479	Trial comparisons
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): serious adverse events	171 of 347	200 of 351	698	NCT03710603	Trial comparisons
Bortezomib + Rituximab vs Rituximab: serious adverse events	59 of 334	37 of 339	673	NCT00312845	Trial comparisons
Bortezomib + Rituximab vs Rituximab: Overall Response Rate	199 of 315	160 of 324	639	NCT00312845	Trial comparisons

1 to 10 of 181

See all 181 comparisons in its trials

Papers from its trials518

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38889735	RESULT	1	PubMed
38820500	RESULT	1	PubMed
35660812	RESULT	1	PubMed
35511184	RESULT	1	PubMed
35271306	RESULT	2	PubMed
35132679	RESULT	2	PubMed
34529931	RESULT	1	PubMed
33947178	RESULT	1	PubMed
33478922	RESULT	1	PubMed
33152759	RESULT	1	PubMed

1 to 10 of 518

See all 518 papers from its trials

Tests in its trials1

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome
Verbal Learning	1	0

Source ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL325041

GET https://conductscience.org/api/drugs/v1/CHEMBL325041/targets?page=2

API reference For AI assistants